Novel protein biomarkers for risk stratification and personalized medicine
Nephrology Dialysis Transplantation · 2026
DOI: 10.1093/ndt/gfag068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, 2026. Verfasst von Erik Moedt und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Biomarkers, Clusterin, Epidermal Growth Factor, Precision Medicine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: STADAPHARM GmbH, European Union.
Abstract (Originalsprache)
Background and hypothesis Albuminuria is widely used to monitor chronic kidney disease (CKD) and treatment response but is subject to variability and primarily reflects glomerular injury. Urinary clusterin and epidermal growth factor (uEGF) are associated with tubular injury and repair, respectively, and may serve as mechanism-informed pharmacodynamic biomarkers. We investigated responses of urinary clusterin and uEGF to endothelin receptor antagonists (ERAs) and sodium–glucose cotransporter 2 inhibitors (SGLT2i), respectively, in CKD.
Methods
We evaluated changes in urinary clusterin-to-creatinine ratio (uCLU/Cr) and uEGF-to-creatinine ratio (uEGF/Cr) in two randomized CKD trial populations. Effects of ERA on uCLU/Cr and endothelin-1 (ET-1) were assessed during the atrasentan enrichment phase of SONAR (Study of Diabetic Nephropathy with Atrasentan), and effects of SGLT2i on uEGF/Cr were examined in DAPA-CKD (Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease) across different CKD etiologies, diabetes status, and glycemic control. Associations between uEGF/Cr and intrarenal EGF messenger RNA (mRNA) expression were examined using kidney biopsy single-cell RNA sequencing data.
Results
After 6 weeks of treatment with atrasentan, uCLU/Cr decreased by 46.3% (95% confidence interval [CI]: −57.8 to −37.1), while serum ET-1 increased by 23.4% (95% CI 19.2–27.4). There were no effects on serum clusterin and only a numerical decrease in urinary ET-1. Baseline uCLU/Cr correlated significantly with urinary ET-1 (Pearson r = 0.65, P < .0001). In DAPA-CKD, dapagliflozin attenuated the decline in uEGF/Cr over 1 year, with heterogeneity across CKD etiologies. Relative increases were greatest in diabetic kidney disease and absent in glomerulonephritis and hypertensive nephropathy. Similarly, effects were larger in those with type 2 diabetes and higher baseline HbA1c. Tubular EGF mRNA expression correlated positively with uEGF/Cr.
Conclusions
Urinary clusterin and uEGF are mechanism-informed pharmacodynamic biomarkers reflecting distinct intrarenal pathways engaged by ERA and SGLT2i therapy, respectively. These biomarkers complement albuminuria by capturing tubular injury and repair, providing a more comprehensive biological assessment of treatment effects and heterogeneity in CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
- Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
- Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
ORCID-Profile: Erik Moedt, Hiddo J L Heerspink
Förderung
- STADAPHARM GmbH
- European Union
Zitieren
APA
Moedt, E., Ju, W., Nair, V., Bjornstad, P., Kretzler, M., & Heerspink, H. J. L. (2026). Novel protein biomarkers for risk stratification and personalized medicine. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag068
Vancouver
Moedt E, Ju W, Nair V, Bjornstad P, Kretzler M, Heerspink HJL. Novel protein biomarkers for risk stratification and personalized medicine. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag068
BibTeX
@article{Moedt2026,
author = {Moedt, Erik and Ju, Wenjun and Nair, Viji and Bjornstad, Petter and Kretzler, Matthias and Heerspink, Hiddo J L},
title = {Novel protein biomarkers for risk stratification and personalized medicine},
journal = {Nephrology Dialysis Transplantation},
year = {2026},
doi = {10.1093/ndt/gfag068}
}
EUVIMED